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E levas em ti guardado 
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Capa negra de saudade 
No momento da partida 
Segredos desta cidade 
Levo comigo p'ra vida 
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ABSTRACT: Metastatic diseases are the main cause of death of cancer patients. Thus, treating cancer disease requires therapies capable of 
treating primary tumors but also able to eradicate distant secondary diseases. Photodynamic therapy (PDT) with redaporfin has revealed prom-
ising results, with high percentage of cures of subcutaneous tumors along with the ability to stimulate the immune system. Our purpose was to 
develop a protocol for an animal model (BALB/c mice with orthotopic 4T1 mammary carcinoma tumor) that can be used to compare surgery 
against PDT in the elimination of the primary tumor and the control of metastasis. BALB/c mice were inoculated with different number of 
4T1-luc2 cells in the abdominal mammary gland. The tumor kinetics was followed to assess the onset of metastatic disease by bioluminescence 
imaging.  The first detection of metastases in the animals subjected to surgery was observed 27 days after inoculation. The higher percentage of 
metastization corresponded to the inoculation of 2x104 cells.  The resistance of 4T1 tumors and the location of the tumor are a challenge to 
PDT. The optimization of PDT with redaporfin proved difficult to treat and may require new strategies capable of potentiate PDT impact on 
the primary tumor and minimize the adverse effects in the surrounding healthy tissues, thus enabling the evaluation of potential effects in distant 
metastasis.
ABBREVIATIONS 
PDT, photodynamic therapy; PS, photosensitizer; ROS, reactive oxy-
gen species; F2BMet (or redaporfin), 5,10,15,20-tetrakis(2,6-difluoro-
3-N-methylsulfamoylphenyl)bacteriochlorin; HPD, hematoporphyrin 
derivative; DLI, drug-to-light interval; ECM, extracellular matrix; BLI, 
bioluminescence imaging; Tregs; regulatory T cells; IL6, interleukin 6; 
APC, antigen-presenting cells. 
INTRODUCTION 
Photodynamic therapy (PDT) is a treatment modality based on 3 
essential components which are individually nontoxic: photosensi-
tizer (PS), light and oxygen. The photosensitizer is administrated ei-
ther systemically, locally or topically to a patient bearing a lesion, fre-
quently a cancer disease, followed by irradiation of the lesion at a 
wavelength corresponding to an absorbance band of the PS. This il-
lumination in the presence of oxygen leads to the generation of cy-
totoxic species and consequently leads to a series of events that cause 
direct tumor cell death, damage to the microvasculature and induce 
a local inflammatory reaction1,2. 
The PS in the ground state has its electrons populating the lowest 
energy molecular orbitals. The two electrons populating each orbital 
have opposite spins, hence the ground state of the PS is a singlet state 
(S0). After the absorption of light one of these electron is boosted 
into a high-energy orbital originating the first excited singlet state 
(S1). This is a short-lived (nanoseconds) species that can lose its en-
ergy by emitting light by fluorescence or by radiationless transitions 
into heat. The S1 state of PS can undergo intersystem crossing 
whereby the spin of the excited electron inverts to form a relatively 
long-lived (microseconds) excited triplet-state (T1) that has two 
electrons with the same spin in the two highest singly occupied mo-
lecular orbitals. This T1 state may undergo two different pathways: 
in type 1 reactions it can react directly with a substrate or with oxy-
gen and transfer a proton or an electron to form a radical; in type 2 
reactions the triplet state of the PS can transfer its energy directly to 
the molecular oxygen to form excited-state singlet oxygen3.  
The radical species generated, such as the superoxide ion (O2.-), 
may produce other reactive species such as H2O2 or �O. in biologi-
cal media, which together with the singlet oxygen from type 2 reac-
tions are designated reactive oxygen species (ROS).  ROS are oxi-
dizing agents that can react with many biological molecules, includ-
ing the DNA. Although cells have some capability of repairing oxi-
dative damage, excessive impairment can cause mutations and lead 
to cell death. However, due to the high reactivity and short half-life 
of these species, oxidative damage only affect molecules close to the 
volume of ROS production (volumes of PS localization). 
How light spread in the target tissue may also have different im-
pacts in PDT efficacy, as it can be absorbed or scattered when it en-
ters tissue, depending on tissue type and light wavelength. Due to 
the absorption of important tissue chromophores like oxy, deoxyhe-
moglobin and melanin at the visible and the occurrence of water ab-
sorption at wavelengths greater than 1300 nm, the optimum wave-
length window in tissue occurs between 600-800 nm, known as the 
phototherapeutic window3. Usually as the PS is a fluorescent and 
photochemically active molecule, both imaging and detection strat-
egies can be applied in PDT protocols. This dual function is an ad-
vantage. 
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Characteristics of the ideal PS have been extensively described 
over the last years. PS should have low dark toxicity, absorb light in 
the red or far-red wavelengths (600-800 nm), where tissues have 
higher optical penetration (ϱ= 2.3 mm at 750 nm)4, and high absorp-
tion bands to minimize the dose of PS needed to achieve the desired 
effect. The ideal PS should have a simple synthesis, be a pure com-
pound, have a long shelf-life and a relatively rapid clearance from 
normal tissues to minimize the phototoxic side effects. Other desir-
able properties of PS agents have been described in literature1,3,5–7. 
The time elapsed between PS administration and tumor illumina-
tion, known as drug-to-light interval (DLI), influences the location 
of the PS and can be a critical component of controlling PDT. Vas-
cular therapy is a PDT modality that involves the irradiation of the 
tumor area less than 30 minutes after compound administration, 
meaning that the PS is still on the vasculature and originating dam-
ages in vessels.1 With short DLI protocols, the clearance effects are 
still minimal, requiring lower doses to achieve the desired effect (im-
proved cost-effectiveness) when compared with higher DLI inter-
vals.  The administration of PS with larger DLI (such as 72h), which 
enables the compound to accumulate inside or nearby cancer cells, 
are designated as cellular protocols5.  
The adverse effects reported for PDT are related to the long-last-
ing photosensitivity, pain during some treatments protocols and ex-
cessive healthy tissue destruction at the treated area1,3. 
The majority of the PS are based on tetrapyrrole macrocycle found 
in natural occurring pigments such as heme chlorophyll and bacteri-
ochlorophyll. Tetrapyrrole macrocycles usually have a relatively 
large absorption band in the region of 400 nm known as the Soret 
band, and a set of progressively smaller absorption bands at longer 
wavelengths known as the Q-bands. Porphyrins have the longest 
wavelength absorption bands in the region of 630 nm but these tend 
to be weak. Chlorins are tetrapyrroles with the double bond in one 
pyrrole ring reduced, which shifts the longest wavelength absorption 
band to the region of 650-690 nm and increases several folds the ab-
sorptivity. Both these factors are highly desirable for PDT. Bacterio-
chlorins have the absorption band shifted even further into the red 
and increased further in magnitude due to the two pyrroles rings 
with reduced double bonds3. 
The first PS to be clinically employed for cancer therapy was hem-
atoporphyrin derivative (HPD), a purified form of which, porfimer 
sodium, was later commercialized as Photofrin8. Although porfimer 
sodium is still the most widely employed PS, it has some disad-
vantages such as the long-lasting photosensitivity and the relatively 
low absorbance at 630 nm. There have been major efforts among sci-
entists to develop second-generation PSs and several hundreds have 
been proposed as potential PS for anticancer PDT1.  
Temoporfin is a chlorin photosensitizer characterized by long 
plasma half-lives (t1/2 = 45.4 h) and is prescribed with drug-to-light 
intervals of 4-6 days. This favors higher tumor selectivity but also 
prolonged skin photosensitivity9,10. Verteporfin is another photosen-
sitizer that has been licensed for the treatment of age-related macular 
degeneration which is characterized by a reduced period of photo-
sensitivity (t1/2 = 5-6 h) when compared with temoporfin. Ver-
teporfin is currently in clinical trials on pancreatic cancer11,12. 
Redaporfin is a photostable bacteriochlorin with intense infra-red 
absorption, high yield of ROS generation, high phototoxicity, low 
skin photosensitivity and favorable pharmacokinetics13,14. The opti-
mized PDT treatment regime leads to significant long-term survival 
rates, with 86% cure rate in BALB/c mice with subcutaneously im-
planted CT26 tumors, but no cures in BALB/c nude mice with the 
same tumor model, revealing the significance of the immune system.  
The result of the oxidative stress from PDT treatments gives a mix-
ture of apoptotic and necrotic cell death and the balance among dif-
ferent cell death pathways is dependent of several PDT parameters, 
such as the total PDT dose, the drug dose, the oxygen concentration, 
the cell type and the localization of the PS inside tumor cells. This 
oxidative stress usually induces immune modulation effects, such as 
the expression of tumor antigens, shortly after the treatment, charac-
terized by a strong acute inflammation localized in the treated area2. 
This acute inflammatory response results in an influx of various im-
mune cells, such as neutrophils, immature dendritic cells and macro-
phages into the injured area, which are responsible for ensuring the 
removal of the damaged cells and promoting local healing15,16. Alt-
hough, in part, this is a tumor antigen nonspecific response by the 
innate immune system, many studies have demonstrated that PDT 
may induce multiple danger signals capable of triggering antigen-
presenting cell (APC), such as B cells, macrophages and dendritic 
cells. APC became activated and then trigger T lymphocytes 
through presentation of tumor antigens. This activation may elicit 
an adaptive immune antitumor effect responsible for eliminating 
surviving cancer cells escaped to the direct effects of PDT but also 
other distant cancer cells1,2,17,18. Thus, in response to the treatment, 
cancer cells die triggering a tumor-specific immune response and 
this is designated as immunogenic cell death.18  
Evidence that local PDT with redaporfin can have systemic effects 
has been found in many experiments: cured mice rechallenged over 
3 months later with CT26 rejected the tumor cells in 67% of the 
cases19; it was observed an antitumor effect in a second untreated tu-
mor in an animal bearing two distant tumors after the treatment of 
one of them; and the stimulation of the immune system that was re-
cently confirmed, revealing an increase of neutrophils number and 
secreted cytokines after treatment (unpublished data). PDT with 
redaporfin also reduced lung metastasis in a pseudo metastatic 
model, when mice with subcutaneous CT26 tumors where treated 5 
days after the additional intravenous injection of CT26 cells19. 
Redaporfin is currently in clinical trials on advanced head and neck 
cancer (ClinicalTrials.gov Identifier: NCT02070432). 
Metastasis are the main cause of death in cancer patients, more 
than 90% of cancer deaths are the result of metastasis20.  Thus, treat-
ing cancer disease requires therapies capable of treating primary tu-
mors but also able to eradicate distant secondary diseases21. 
The metastatic process is an extremely complex process and is pre-
sumed that only a small fraction of tumor cells have the ability to me-
tastasize. Metastasization consists in the detachment of epithelial 
cells from the extracellular matrix (ECM), infiltration in the blood 
and/or lymphatic system, survival and growth at the metastatic 
site22.  
This work intends to develop a protocol for an animal model that 
can be used to compare surgery against PDT in the elimination of 
the primary tumor and control of metastasis. In this study we used 
the poorly immunogenic BALB/c-derived mouse mammary carci-
noma, 4T1, which mimics the human stage IV breast cancer in its 
immunogenicity, metastatic properties and growth characteristics. 
4T1 tumors are highly aggressive and spontaneously metastasize 
throughout the body, in a pattern similar to human breast cancer, to 
lymph nodes, lungs, liver, brain, blood and bone 23–27.  
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EXPERIMENTAL SECTION 
 
MATERIALS AND METHODS 
 
Chemicals 
5, 10, 15, 20-Tetrakis(2, 6– difluoro- 3– N– methylsulfamoylphe-
nyl)bacteriochlorin (F2BMet or redaporfin) was recently de-
scribed14. Luzitin SA (Coimbra, Portugal) provided redaporfin as a 
powder in a sealed amber glass vial under N2 atmosphere. D-Lucif-
erin was purchased from Caliper Life Sciences. Details on drug for-
mulations are presented in Supplementary Materials. 
 
Cell lines and cell culturing 
4T1 and 4T1-luc2 cell lines were purchased from ATCC and Per-
kin Elmer, respectively, and were maintained in RPMI medium 1640 
supplemented with 10% fetal bovine serum, 1% penicillin/strepto-
mycin at 37oC in 5% CO2 and 95% humidity. 4T1-luc2 is a luciferase 
expressing cell line which was stably transfected with firefly lucifer-
ase gene (luc2) and allows to access the metastasis onset in animal 
models with bioluminescence imaging (BLI). All reagents were pur-
chased from Sigma Life Sciences unless stated otherwise. 
 
In vitro PDT treatments 
From 4T1 and 4T1-luc2 cell lines, cells were seeded into 96-well 
plate at a cell density of 6000 and 7000 cells/well, respectively. After 
24 h redaporfin was administered to both cell lines at several concen-
trations, from 0.075 to 10 µM. After an incubation period of 20 h 
cells were washed 3 times with PBS and, immediately after, cells were 
irradiated with a light emitting diode, LED, (750±20 nm) with a 
light dose of 0.1 J/cm2. In order to evaluate the viability it was per-
formed the Alamar blue assay 24 h after LED irradiation. Details on 
Alamar blue protocol are presented in Supplementary Materials. 
 
In vitro PDT treatments in the presence of anes-
thesia 
4T1 cells were seeded at a cell density of 7000 cells/well and 24 h 
after plating, cells were incubated with redaporfin alone and with dif-
ferent concentrations of anesthesia (a mixture of ketamine: xylazine 
in 5:1 ratio), in ratio w:w. After an incubation period of 20 h cells 
were washed 3 times with PBS and, immediately after, cells were ir-
radiated with a light emitting diode, LED, (750±20 nm) with a light 
dose of 0.1 J/cm2. In order to evaluate the viability it was performed 
the Alamar blue assay 24 h after LED irradiation. 
 
Metastatic Animal Model Optimization 
Female BALB/c mice were obtained from Charles River Labora-
tories® (Barcelona, Spain) and were used with 9 to 12 weeks of age, 
weighing 18-24 grams. Before each tumor inoculation, all of the hair 
in the mammary gland region was removed with depilatory cream. 
For metastatic model optimization, different number of 4T1-luc2 
cells which were taken up in 0.05 mL of RPMI without serum and 
antibiotics (1x104, 2x104, 5x104 and 10x104 cells) and were orthotop-
ically transplanted into the abdominal mammary gland of each ani-
mal. Before inoculation animals were anesthetized with a mixture of 
ketamine/xylazine (5:1), 120 mg/kg and 10 mg/kg, respectively.  
Tumor size was measured with calipers bi-weekly once tumors be-
came palpable and mean tumor volume was calculated with the for-
mula (a x b2)/2, a referring to the largest and b to the shortest diam-
eter of the tumor.  Animals were submitted to surgery when the tu-
mor diameter reached 4 mm. BLI of live animals was initiated at 27 
days after cell line injection and performed weekly until day 41, and 
then animals were sacrificed. 
 
Mouse Tumor Model 
For the tumor establishment 2x104 4T1-luc2 cells were taken up 
in 0.05 mL of RPMI without serum and antibiotics and were ortho-
topically transplanted into the abdominal mammary gland of each 
animal. Tumor size was measured with calipers bi-weekly once tu-
mors became palpable and mean tumor volume was calculated with 
the formula (a x b2)/2. Primary tumors were treated 7-11 days after 
the inoculation when tumor diameter reached 4-5 mm. Control ani-
mals were submitted to surgery and animals were sacrificed when the 
tumor diameter reaches 8-10 mm or when mice became moribund 
(i.e., weight loss > 20%, visible prostration). 
 
PDT regimens 
Tumor illumination protocols described in Table 1 used a contin-
uous wave (CW) laser with emission at 749 nm supplied by Omi-
cron which was handled close to the surface of the tumor with a spe-
cific diameter of the laser spot. Tumor dimensions were determined 
before the illumination. 
 
In vivo luminescence imaging 
Detection of metastasis by bioluminescence imaging (BLI) was 
performed using a charge-coupled device camera–based biolumi-
nescence imaging system (IVIS Lumina XR, Caliper Life Sciences, 
Hopkinton MA; exposure time 1–300 sec, binning 8, field of view 4-
23 cm). Before image acquisition, all of the hair in the frontal region 
was removed with depilatory cream. After the mice were anesthe-
tized with a mixture of ketamine/xylazine (5:1), 120 mg/kg and 10 
mg/kg, respectively, D-luciferin potassium salt (150 mg/kg) were 
intraperitoneally injected to the mice 5 minutes prior to imaging ac-
quisition. Signal was measured and recorded as total flux (pho-
tons/sec) and data was analyzed with Living Image software (Cali-
per Live Sciences). 
 
Statistical Analyses 
All of the measured values are presented as mean ± SD. Statistical 
analyses were performed using Prism v. 4.5 (GraphPad Software). 
Data were analyzed with unpaired two-tailed Student’s t tests or one-
way analysis of variance (ANOVA) tests as indicated in respective 
figure legends. Details on statistical data are presented in Supple-
mentary Materials. 
 
RESULTS 
 
In vitro PDT treatments – Cell lines comparison 
In order to evaluate if there were any significant differences be-
tween in vitro PDT treatments in parental and transfected cells, 
PDT treatments were performed in both cell lines, 4T1 and 4T1-
luc2, with a range of concentrations of redaporfin to compare the 
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IC50 value for each cell line. From our results, IC50 value for 4T1 
cell line is 1.3 ± 0.4 µM and for 4T1-luc2 cell line is 1.1 ± 0.3 µM. 
Although apparently it seems to exist some differences in the manip-
ulation and fragility of 4T1-luc2 when compared to 4T1, differences 
between the IC50 values were not statistically significant using a un-
paired two-tailed Student’s t test with P> 0.05 (p  = 0.6). On the 
other hand, when compared with other cell lines the IC50 of mam-
mary carcinoma cell line is relatively lower, indicating that this tumor 
cell line appeared to be more vulnerable in vitro when compared to 
other cancer lines undergoing PDT14. 
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Figure 1. Data from in vitro PDT treatments with redaporfin. A 
Dose-response curves of 4T1 and 4T1-luc2 cell lines to PDT treat-
ments with different concentrations of redaporfin.  B IC50 values for 
each cell line which reveal no statistical differences between cell lines 
vulnerability to redaporfin PDT. The statistical significance of data 
the Student’s t test was performed at a P set at 0.05 (p=0.6). 
 
Metastatic Animal Model  
Classical orthotopic models are impractical for evaluation of treat-
ment’s efficacy since they require large numbers of animals to be sac-
rificed at each time point. The cell line used in this work was trans-
fected with firefly luciferase gene (luc2) which allows to follow the 
metastasis onset and growth without sacrificing the animals.  
To confirm the metastatic potential of 4T1 mammary carcinoma 
and to optimize a metastatic model capable of comparing metastasi-
zation after surgery and after PDT treatment, mice were challenged 
with different number of cancer cells and metastasis establishment 
was assessed after animals were subjected to surgery.  
Since the number of inoculated cells affects the onset and kinetics 
of tumor growth, animals were submitted to surgery when the largest 
diameter of the tumor attained 4 mm, between 7 and 17 days after 
the cell inoculation, as is schematized in Figure 2. Metastasization 
was monitored by bioluminescent imaging between days 27 and 41, 
and then the animals were sacrificed.  
The first detection of metastases in animals subjected to surgery 
was observed 27 days after inoculation (Supplementary Infor-
mation) and the higher percentage of metastasization (75%) corre-
sponded to the inoculation of 2x104 cells (Figure 3). 
 
 
 
Figure 2. Overview of metastatic model optimization. A Schematic out-
line of metastatic model optimization protocol: Different number of 
cells were inoculated in the mammary gland (1x104, 2x104, 5x104 and 
1x105 cells) and surgery was performed when tumor diameter attained 4 
mm. Lung imaging was performed on days 27, 34 and 41. B IVIS image 
and photograph of 4T1-luc2 mammary carcinoma tumor (2x105 inocu-
lated cells) at day 14 (IVIS acquisition settings: exposure time 2 sec, bin-
ning 4, field of view 10 cm). 
 
In vitro PDT treatments in the presence of anes-
thesia 
Previous PDT protocols with redaporfin always involved irradia-
tion of the tumor in the animal thigh, and the illumination of tumors 
could be performed while animals were maintained motionless by 
the investigator.  However, in the animal model studied in this work, 
the inoculation of the tumor is in the abdominal area, the irradiation 
may cause some discomfort on the animal and it could be very diffi-
cult to keep the animal motionless. The motion of the animal during 
the treatment may have a major impact in PDT efficacy. The move-
ment of the animal may change spot of irradiation and light scatter-
ing and therefore the total dose of light delivered to the target tissues. 
This may reduce the impact of PDT on the tumor and increase dam-
age to the adjacent healthy tissues. Thus, it was necessary to anesthe-
tize animals before the irradiation procedure. 
In vitro PDT treatments in the presence of anesthesia were re-
quired to confirm that anesthesia would not have an antioxidant ef-
fect during PDT treatments, as it is suggested with some anesthetic 
drugs28,29, that could protect cancer cells from cytotoxic effects of 
PDT and could justify preliminary results with no impact in 4T1 tu-
mors after treatments. From our results in Figure 4 it was demon-
strated that the presence of anesthesia from high to low concentra-
tion during in vitro PDT protocols do not affect the efficacy of PDT. 
In fact, the presence of anesthesia in higher concentrations appar-
ently seems to have some synergetic cytotoxic effect with redaporfin. 
However, these differences were not statistical significant. 
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Figure 3. Detection of lung metastasis in vivo. Assessment of lung 
metastasis was performed by bioluminescent imaging. D-luciferin 
was injected 5 min prior to images acquisition and bioluminescent 
images were taken using an IVIS Lumina XR. Data refers to imaging 
41 days after tumor inoculation. Higher percentage of metastasiza-
tion was obtain with the inoculation of 2x104 cells, corresponding to 
75 % of metastasized animals.  
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Figure 4. Data from in vitro PDT treatments in 4T1-luc2 cell line in the 
presence of anesthesia. Cells were incubated with 5 µM redaporfin alone 
and with different concentrations of anesthesia, ratio (w/w), (20 h incu-
bation) which revealed no statistical differences when compared with 
PDT with redaporfin alone. To evaluate the statistical significance of 
data the one-way ANOVA followed by Dunnett’s Multiple Comparison 
test was performed at a P set at 0.05. 
 
In vivo PDT regimens 
The optimization of PDT protocol was initiated with the opti-
mized PDT parameters for CT26 tumor model, Protocol 1 in Table 
1, which was described recently19 and offered 86 % cure rate in 
BALB/c mice. However, in the orthotopic mammary carcinoma 
model these conditions revealed to be potentially lethal and with no 
impact on tumors. Necropsies of animals submitted to this protocol 
revealed major impact in the adjacent healthy tissues: liver, kidney 
and small intestine.  
The following protocols resulted in changes in drug dose and in 
diameter of irradiation, but still with no impact on the tumors. Com-
binatory therapies were introduced to reduce the vascular doses of 
PS (with DLI of 0.25 h) and were sequentially replaced by cellular 
doses (with DLI of 72h), which could enabled higher dosage of PS 
and achieve a more localized treatment. Although many regimens 
were explored balancing light and PS dose this optimization was not 
successful in means of achieving an effective treatment capable of 
eradicate or reduce the tumor kinetic growth. The greatest impact 
on tumors was obtained through protocol 9 that led to necrosis in 
the surface of the tumors after 48-72 h, however tumors started to 
regrowth after 72h (Figure 5). The kinetics of tumor growth of pro-
tocol 9 and 11 in comparison with a control group (with no treat-
ment) are represented in Figure 6. 
 
 
Figure 5. Impact of PDT of protocol 9, described in Table 1.  A - 
before PDT; B – 24 h after PDT; C – 48 h after PDT. Tumor regrow 
72 h after PDT. 
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Figure 6. Kinetics of 4T1 tumor growth: comparison between con-
trol group (animals submitted to no treatment), PDT protocol 9 
(treatment on day 18) and PDT protocol 11(treatment on day 10). 
DISCUSSION 
The 4T1 tumor is highly invasive and develops spontaneous me-
tastasis from the primary tumor. In comparison with the clinical sit-
uation, the primary tumor can be surgically removed and the meta-
static foci remains intact, so the metastatic disease can be studied in 
animal models24. Non-invasive whole body bioluminescence imag-
ing allows repeated, real-time in vivo monitoring of tumor growth in 
experimental animals, regardless of tumor locations adding ad-
vantages over traditional models.  
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Table 1. Studies of PDT regimens for 4T1-luc2 orthotopic tumor illumination protocol optimization. 
 
 
Our results from the metastatic model optimization showed that 
the inoculation of 2x104 cells can originate metastasization in 75% of 
the cases, being able to be used as a metastatic model that mimics the 
human cases and allows non-invasive detection and quantification of 
metastasis in live animals as means of assessing drug/treatment effi-
cacy. Our results confirmed that the inoculation of a smaller number 
of cells facilitates the metastization process, as it is mentioned in lit-
erature24,30.  
Vascular PDT with redaporfin found remarkably efficient in the 
treatment of CT26 tumors in animals’ thigh19. Under these condi-
tions the damages occur mainly in the vasculature of tumors and 
generating tumor hypoxia and starvation, which leads to tumor abla-
tion and stimulation of the immune system. However, the optimized 
protocol for CT26 tumors did not give the same kind of results in 
4T1 models, which originated 43% of treatment survival, and the an-
imals that survived to the treatment revealed no impact on tumors. 
This results may be due to the fact of 4T1 tumors being described as 
highly vascularized tumors15,24, thus, the protocol that leads to de-
struction of CT26 tumor vasculature may not be enough to cause 
the same effect in the robust vessels of 4T1 tumors. 
The aggressive and invasive characteristics and the location of 4T1 
tumors represents a challenge to PDT. The requisite of administer-
ing higher PS (redaporfin) and light doses to achieve a significant 
impact on the tumor, has the limitation of the tumor location in the 
abdominal region. The majority of the drugs have tendency to accu-
mulate in liver and kidneys (elimination organs) and adverse effects 
of the treatment in adjacent vital organs, such as liver, kidneys and 
bowel may limit the survival of animals to the treatment.  
Cellular protocols with DLI of 72 h which enables the compound 
to accumulate inside or nearby cancer cells, appeared to be more 
suitable than vascular methodologies. Although we verified some ef-
fects of PDT on tumors (edema and necrosis), the treatments were 
not effective and the adverse effects in the adjacent tissues still re-
mained. The concentration of PS in organs of elimination is always 
higher than the accumulation in tumor13 and can increase over time 
due to drug clearance effects. Excessive damages on vital organs may 
also occur mainly due to the small dimensions of BALB/c mice, in 
which the distance between organs and the irradiation spot is not 
sufficient to avoid these effects. This fact might be circumvented 
through the application of models with larger animals, such as the 
wistar rat model. 
PDT efficacy is also limited by light fluence rate (irradiance) of tu-
mor illumination. High fluence rates may originate photobleaching 
of PS and high percentages of singlet oxygen formation leading to 
oxygen consumption. This excessive consumption may decrease the 
PDT efficacy since volume of oxygenated and therefore PDT-
sensitive tissue are reduced. On the other hand, low fluence rates 
may remain at the sub-lethal damage levels and originate ineffective 
treatments19,31. 
Irradiations with a diameter spot greater than the size of the tumor 
is important to the effectiveness of the treatment as it inhibits the re-
supply of nutrients to the tumor. On the other hand, the increase of 
the irradiation spot can lead to excessive destruction of adjacent tis-
sues. 19 During treatment optimization in this study, the spot of irra-
diation was diminished in order to minimize the adverse effects on 
adjacent tissues. However, the outcome of treatments did not im-
prove.  
A number of studies have also tried to obtain an effective treat-
ments with 4T1 metastatic model, however outcomes were not sat-
isfactory. Gollnick’s group demonstrated a significant reduction of 
lung tumors in an experimental metastasis model with EMT6 mam-
mary carcinoma cells, but the 4T1 metastatic model proved difficult 
to treat with PDT with Photofrin. Although, primary tumor re-
pressed initially after PDT, it grew up in one week and spontaneous 
lung metastasis were not controlled with this treatment.15 During 
these studies it was demonstrated that the number of regulatory T 
cells (Tregs) is significantly higher ( 3000 times) in 4T1 tumors 
rather than EMT6 tumors before PDT. This may suggests that Tregs 
may contribute to suppression of tumor response.15 It has been also 
demonstrated that IL6 is a cytokine that has been shown to play a 
Protocol 
Drug-to-light interval 
(DLI)(h) 
Drug dose 
(mg/kg) 
Light dose 
(J/cm2) 
Laser Power 
(mW) 
Diameter 
(cm) 
Survivals to the treat-
ment (%) 
Impact on the tumor 
1 0.25 1.00 50 173 1.3 43 no impact 
2 0.25 0.75 50 173 1.3 100 no impact 
3 0.25 0.75 50 173 1.1 100 no impact 
4 0.25 1.00 50 173 1.1 100 no impact 
5 72 1.00 100 173 1.3 100 necrosis 
6 72 & 0.25 1.00 & 0.5 80 173 1.3 0 - 
7 72 & 0.25 1.00 & 0.5 60 173 1.3 100 no impact 
8 24 & 0.25 1.00 & 0.5 50 173 1.0 0 - 
9 144 & 72 & 0.25 1.00 & 1.00 & 0.4 50 173 1.0 100 necrosis 
10 72 & 0.25 2.00 & 0.4 50 173 1.0 0 - 
11 72 2.00 50 173 1.0 100 edema 
12 72 2.00 75 103 1.0 0 edema and  necrosis 
13 72 2.00 65 103 1.0 0 edema 
7 
major effect in T-cell proliferation, survival and function32, and its 
production appears to be enhanced after PDT in 4T1 tumors. How-
ever, IL6 has been shown to potentiate tumor resistance and survival 
to PDT and to inhibit therapy enhancement of immune memory33.  
PDT treatments with redaporfin still need to be further optimized 
for this metastatic model, even though some of the barriers have 
been predicted. This experiments revealed essential evidences about 
4T1 tumor responses to PDT treatment and several strategies may 
still be challenged with this cell line.  
Frontal irradiation already revealed many limitations and the im-
plementation of interstitial irradiation may circumvent some of 
them, such as the undesirable effects of light scattering in surround-
ing tissues and the need to ensure a homogenous illumination of all 
tumor bulk34,35.  
Combinatory therapies involving a large range of immunoadju-
vants have been considered in literature as possible enhancers of 
PDT efficacy through the immune system stimulation16,36. Low dose 
cyclophosphamide is a traditional cytotoxic cancer drug that dam-
ages tumor DNA and has been recognized for inducing an antitumor 
immune response through the depletion of regulatory T cells36–39, 
which are recognized as suppressors of immune system response and 
are highly present in 4T1 tumors after in immune-augmenting treat-
ments in tumor bearing hosts40. 
Hamblin et al.41 also used the 4T1 metastatic model to study PDT 
effects with Verteporfin. However, the results shown a relative lack 
of major tumor destruction by PDT alone. The combinatory therapy 
of PDT with CPG-ODN immunoadjuvant in turn had a bigger im-
pact in the treatment of this model, with delay in the local tumor pro-
gression and a corresponding increasing in the survival. 
Many other efforts have been applied to understand PDT mecha-
nisms and to apply strategies to improve PDT impact. Our group 
have been involved in several studies with the purpose of increasing 
PS phototoxicity for instance through the inhibition of dismutase su-
peroxidase (Mn-SOD), which may enhance the capacity of PS to 
transfer an electron to molecular oxygen and consequently enhanc-
ing PDT efficacy (unpublished data). 
 
CONCLUSIONS 
Photodynamic therapy with redaporfin had revealed promising re-
sults, particularly the ability to stimulate an antitumor immune re-
sponse that is responsible for the effectiveness of the optimized pro-
tocol for CT26 models. However, the resistance of 4T1 cells and the 
location of the tumor are a challenge to PDT. Effective treatments 
requires new strategies capable of providing an improved impact on 
the primary tumor without generating excessive damage in the sur-
rounding healthy tissues, thus enabling the evaluation of potential 
effects in distant metastasis. 
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SUPPLEMENTARY INFORMATION 
 
Materials and Methods 
 
 
Figure S1. Molecular structure of 5,10,15,20-tetrakis(2,6-dif luoro-3-N-ethylsulfamoylphenyl) 
bacteriochlorin (F 2BMet or  redaporfin). 
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Graph S1. Spectra of normalized absorption of redaporfin in DMSO (black), RPMI (red) and in 
vivo  formulation (blue).  
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Preparation of culture medium 
For 1 L of RPMI medium, 10.4 g of RPMI-1640, 2.4 g of HEPES and 2 g of sodium bicarbonate were 
added to 890 mL of milli-Q water, 100 mL of heat-inactivated fetal bovine serum (FBS), and 10 mL of 
penicillin-streptomycin (PS). The mixture was stirred until a homogeneous solution was obtained.  
Solution was filtered, inside the laminar flow hood, through a filter with a porosity of 0.2 μm. All 
reagents were purchased from Sigma Life Sciences unless stated otherwise. 
 
Preparation of phosphate buffer saline (PBS) 
For 1 L of PBS, 0.2 g of potassium phosphate monobasic anhydrous (KH2PO4), 0.2 g potassium 
chloride (KCl), 1.15 g of sodium phosphate dibasic (Na2HPO4) and 0.4 g of sodium chloride (NaCl) 
were added to 1 L of milli-Q water. The mixture was stirred until a homogeneous solution was obtained 
and then was filtered, inside the laminar flow hood, through a filter with a porosity of 0.2 μm. 
 
Measurement of absorbance 
Absorbance spectra of redaporfin were recorded in UV-visible Recording Spectrophotometer 
(Shimadzu). The samples diluted from stock solutions were measured in quartz cuvettes with an 
optical path of 1 cm. All measurements were performed at room temperature. Concentration of 
redaporfin solution used for all experiments was calculated using Beer-Lambert Law: A = ϲ l c. 
 
In vitro and in vivo formulations 
For cellular assays, stock solutions of redaporfin were prepared in dimethyl sulfoxide (DMSO) (≈ 1-2 
mM). For in vivo intravenous administrations, redaporfin was dissolved in 0.2 % Kolliphor, 1% ethanol 
and 98.8 % NaCl. 
 
Measurement of cell viability by fluorescence – Alamar blue assay 
Measurements of cytotoxicity were performed in 96-well plate using Alamar blue assay by fluorescence. 
After each experiment, cells were washed 3 times and was incubated with 0.01 mg/mL of Alamar blue 
diluted in the respective culture medium. After approximately 2 hours, cell viability was assessed by the 
assessed by fluorescence using a Synergy HT Multi-Mode Microplate Reader (BioTek), λexc = 560 nm 
and λem = 590 nm).  
 
Preparation of anesthesia 
For in vivo and in vitro studies, anesthesia was prepared with a mixture of ketamine and xylazine in a 5:1 
ratio (v:v).  0.750 mL of ketamine (0.1 g/mL) and 0.250 mL (23.3 mg/ml) were added to 4 mL of 
phosphate buffer saline (PBS). Solution was filtered, inside the laminar flow hood, through a filter with 
a porosity of 0.2 μm.   
 
 
  
Figure S2. PDT illumination procedure. 
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Data Results 
 
Table S1 . Cytotoxicity data of in vitro PDT with redaporfin in 4T1 and 4T1-luc2 cell lines. 
Redaporfin 
concentration 
(µM) 
4T1 cell line 4T1-luc2 cell line 
Cell viability (%) Mean SD Cell viability (%) Mean SD 
0.0781 106.51 98.16 111.11 105.26 6.57 106.95 102.09 95.48 101.51 5.76 
0.156 98.05 92.49 104.17 98.24 5.84 98.94 101.22 96.93 99.03 2.14 
0.3125 100.69 79.65 101.45 93.93 12.37 95.87 82.41 93.79 90.69 7.24 
0.625 77.04 61.33 100.73 79.70 19.84 83.64 57.82 86.34 75.94 15.74 
1.25 59.44 44.42 76.90 60.25 16.25 51.40 30.19 61.70 47.77 16.07 
2.5 34.92 27.40 47.47 36.60 10.14 31.51 17.14 32.05 26.90 8.46 
5 24.80 12.79 17.87 18.49 6.03 17.31 9.49 13.34 13.38 3.91 
10 15.69 13.20 9.87 12.92 2.92 12.48 9.44 9.39 10.43 1.77 
 
Table S2. IC50 values of in vitro PDT with redaporfin in 4T1 and 4T1-luc2 cell lines and data from statistical 
significance of cell lines differences, by the Student’s t test at a P set at 0.05. 
Cell line IC50 (µM) 
Mean 
(µM) 
SD  
 (µM) 
P value of 
student’s t test  
4T1 1.2 0.8 2.0 1.3 0.36 
0.6 
4T1-luc2 1.1 0.6 1.6 1.1 0.27 
 
 
Table S3. Cytotoxicity data of in vitro PDT with redaporfin (5 µM) and different concentrations of anesthesia in 
4T1 cell line. 
Redaporfin: 
Anethesia 
(w:w) 
Cell viability (%) Mean SD 
1:0 32.68 16.23 9.22 19.38 12.05 
1:1 32.93 17.88 9.65 20.15 11.81 
1:5 20.13 10.38 9.42 13.31 5.93 
1:10 10.34 8.95 9.46 9.58 0.71 
1:20 9.90 8.53 9.40 9.28 0.69 
1:30 9.31 8.72 9.47 9.17 0.39 
 
Table S4. Statistical significance of data from Table S3 evaluated with the one-way ANOVA followed by 
Dunnett’s Multiple Comparison test was performed at a P set at 0.05. 
Dunnett's Multiple Comparison Test Mean Diff. q 
Significant?  
P < 0.05? 
1:0 vs 1:1 -0,7798 0,1306 No 
1:0 vs 1:5 6,065 1,016 No 
1:0 vs 1:10 9,792 1,640 No 
1:0 vs 1:20 10,10 1,691 No 
1:0 vs 1:30 10,21 1,710 No 
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Table S5. Dark cytotoxicity data of incubation with redaporfin (5 µM) and different concentrations of anesthesia 
in 4T1 cell line. 
Redaporfin: 
Anethesia 
(w:w) 
Cell viability (%) Mean SD 
1:0 111.37 103.69 97.92 104.32 6.75 
1:1 111.86 97.78 92.62 100.75 9.96 
1:5 116.49 101.45 93.39 103.78 11.72 
1:10 118.74 98.87 88.09 101.90 15.55 
1:20 110.81 94.30 76.76 93.96 17.03 
1:30 111.55 88.71 78.52 92.93 16.92 
 
Table S6. Statistical significance of data from Table S5 evaluated with the one-way ANOVA followed by 
Dunnett’s Multiple Comparison test was performed at a P set at 0.05. 
Dunnett's Multiple Comparison 
Test 
Mean Diff. q 
Significant?  
P < 0.05? 
1:0 vs 1:1 3,573 0,3231 No 
1:0 vs 1:5 0,5459 0,04938 No 
1:0 vs 1:10 2,423 0,2192 No 
1:0 vs 1:20 10,37 0,9377 No 
1:0 vs 1:30 11,40 1,031 No 
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Figure S3. Animals submitted to surgery revealed no tumor regrowth, which was confirmed by bioluminescence 
imaging. 
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Figure S4. Imaging data from metastatic model optimization. 4 groups of animals (n=4) were inoculated with 
different concentration of inoculated cells, 1x104, 2x104, 5x104 and 1x105cells, corresponding respectively to 
A, B, C and D groups in the following data. When the largest diameter of tumor attained 4 mm the animals were 
submitted to surgery and metastasis onset was assessed by imaging luminescence 27, 34 and 41 days after tumor 
inoculation. 
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Figure S5. Impact of PDT protocol 9 in 4T1 tumors. After 72 h tumors started to regrow. 
 
Table S8. Tumor volumes (mm3) of animals from protocols described in Table S7. Until protocol 7, the number 
of 4T1-luc2 inoculated cells was 2x105, because the metastatic model was still not optimized. From this, the 
number of inoculated cells was 2x104 cells. 
Protocol 1 
          
Day 4 5 7 11 14 18 21 
    
1 6.3 28.2 18.7 
        
2 12.0 8.1 13.9 
        
3 7.5 14.9 16.2 28.2 40.6 66.0 134.5 
    
4 4.9 5.6 13.0 18.4 78.0 107.9 171.4 
    
5 6.3 6.8 24.0 
        
6 6.9 18.0 21.4 
        
7 9.5 14.9 29.6 49.4 101.3 148.1 175.1 
    
Mean 7.6 13.8 19.5 32.0 73.3 107.3 160.3 
    
SD 2.4 7.9 5.9 15.8 30.6 41.1 22.4 
    
            
Protocol 2 
          
Day 22 25 27 28 29 32 34 36 
   
1 9.1 24.0 51.9 
        
2 5.4 20.7 39.0 117.2 67.6 67.6 128.4 285.4 
   
Mean 7.3 22.3 45.4 
        
SD 2.6 2.3 9.1 
        
            
Protocol 3 
          
Day 18 22 25 27 28 29 32 34 36 40 
 
1 4.6 6.7 10.5 7.4 8.4 11.3 13.0 17.4 28.2 97.2 
 
2 3.4 15.3 36.5 55.2 65.6 76.2 100.9 186.5 184.7 344.4 
 
Mean 4.0 11.0 23.5 31.4 37.0 43.8 57.0 102.0 106.6 220.8 
 
SD 0.9 6.0 18.3 33.8 40.4 45.9 62.1 119.6 110.9 174.8 
 
            
Protocol 4 
          
Day 15 18 22 25 27 28 29 32 34 36 40 
1 9.8 9.5 26.6 51.9 107.9 102.9 124.5 172.5 233.3 251.9 499.9 
2
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Table S8 continuation. Tumor volumes (mm3) of animals from protocols described in Table S7. Until protocol 
7, the number of 4T1-luc2 inoculated cells was 2x105, because the metastatic model was still not optimized. From 
this, the number of inoculated cells was 2x104 cells. 
Protocol 5 
          
Day 6 10 
         
1 18.3 41.8 
         
            
Protocol 6 
          
Day 3 6 10 
        
1 2.7 19.7 42.9 
        
            
Protocol 7 
          
Day 10 
          
1 6.9 
          
            
Protocol 8 
          
Day 6 9 13 16 
       
1 18.5 22.4 48.8 48.8 
       
2 22.4 26.4 61.1 80.0 
       
3 14.3 19.6 52.0 55.4 
       
4 9.0 26.9 55.4 68.1 
       
Mean 16.0 23.8 54.3 63.1 
       
SD 5.0 3.0 4.6 12.0 
       
            
Protocol 9 
          
Day 4 7 11 12 15 18 19 25 
   
1 2.5 14.9 39.7 39.8 72.9 120.8 120.8 368.5 
   
2 1.5 10.5 24.0 35.3 42.5 70.2 74.4 231.2 
   
3 2.8 15.9 40.7 51.6 70.3 117.2 109.8 285.4 
   
Mean 2.3 13.8 34.8 42.2 61.9 102.8 101.7 295.0 
   
SD 0.6 2.9 9.4 8.4 16.8 28.2 24.3 69.2 
   
            
Protocol 10 
          
Day 4 6 7 9 10 11 12 
    
1 3.0 13.3 14.9 21.0 28.7 
      
2 
 
4.0 6.9 11.7 
 
18.4 25.1 
    
3 6.3 6.8 11.2 10.1 17.7 
      
Mean 4.7 8.0 11.0 14.2 23.2 
      
SD 2.3 4.8 4.0 5.9 7.8 
      
            
Protocol 11 
          
Day 6 8 10 13 14 16 20 23 
   
1 6.8 7.8 12.1 
 
27.8 40.4 83.8 163.7 
   
2 4.2 6.1 12.6 25.3 
 
31.0 63.6 175.7 
   
3 9.7 14.5 29.5 
 
44.5 73.7 219.3 338.7 
   
4 3.7 7.8 13.5 37.0 
 
34.7 150.0 199.1 
   
5 5.1 12.0 12.8 
 
43.2 46.7 130.5 220.5 
   
6 5.3 7.5 12.5 31.2 
 
29.2 104.4 122.8 
   
Mean 5.8 9.3 15.5 31.1 38.5 42.6 125.3 203.4 
   
SD 2.2 3.3 6.9 5.9 9.3 16.5 55.6 74.1 
   
22 
 
Table S8 conclusion. Tumor volumes (mm3) of animals from protocols described in Table S6. 
            
Protocol 12 
          
Day 6 7 10 13 14 17 
     
1 1.4 
 
5.1 16.3 18.9 34.2 
     
2 3.5 5.0 10.9 31.9 42.5 
      
3 3.4 6.1 19.5 38.8 42.5 
      
4 5.1 7.8 11.5 36.1 36.0 
      
5 4.2 8.4 19.1 40.7 46.5 
      
6 9.5 11.6 24.5 44.5 43.7 
      
Mean 4.5 7.8 15.1 34.7 38.4 
      
SD 2.7 2.5 7.1 10.0 10.1 
      
            
Protocol 13 
          
Day 6 7 10 13 
       
1 2.1 2.8 4.2 16.9 
       
2 0.0 3.6 5.6 9.0 
       
3 2.3 4.2 5.6 14.4 
       
4 1.8 5.8 6.6 17.2 
       
5 2.3 7.5 9.5 18.4 
       
6 1.5 6.0 7.1 15.8 
       
Mean 1.7 5.0 6.4 15.3 
       
SD 0.9 1.8 1.8 3.3 
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This master project has resulted in one oral communication at II Young Researchers Symposium of the 
Spanish Society of Medicinal Chemistry (12th June 2015, Madrid, Spain) and one poster presentation 
at XXIV Encontro Nacional da Sociedade Portuguesa de Química (1st-3rd July 2015, Coimbra, 
Portugal). The poster is presented below. 
 
